Dyno is hosting the Genetic Agency Technology Conference (GATC) in Boston on November 11th, inspired by the goal of building a world with “genetic agency.” This term describes a person’s ability to take informed action at the genetic level to live a healthier life and acknowledges the efforts of patients working to develop therapeutic options where none currently exist. The conference is driven by a vision of the future where safe, effective, and accessible patient-empowering genetic technologies are a reality, recognizing that this future requires a community—not just one actor—working together with pace to turn powerful emerging technologies into concrete patient impact.

GATC brings together a diverse group of leaders from various sectors, including therapeutic developers, technologists, AI pioneers, entrepreneurs, patients, and advocates. The meeting will cover technological frontiers, firmly grounded in patient impact, with topics like state-of-the-art AI for sequence design, gene editing, and gene delivery as key enabling technologies. Other areas of interest include preclinical development, manufacturing, and regulatory pathways. Compared to traditional conferences, GATC emphasizes highly participatory sessions focused on conversation and connection, built on the assumption that every attendee brings valuable expertise and a common goal.